Saturday 17 October 2026
Export ORGS’s income statement to Excel — free account
Orgenesis Inc.
ORGS Healthcare Biotechnology
Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.
0.06
0.06
Infinity
Follow ORGS
| Dec '24 | Sep '24 | Jun '24 | Mar '24 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 4 | 1 |
+8 more TTM periods Free account |
| 164.62% | 175.12% | 203.46% | 478.19% | ||
| (605.73%) | (145.76%) | (119.30%) | (79.92%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
188.28% | 184.72% | 215.72% | 393.45% | |
Average Days of Receivables |
14.11 | 65.37 | 132.33 | 169.05 | |
Free Cash Flow per Share |
(4.12) | (3.34) | (3.23) | (3.93) | |
Free Cash Flow |
(17.34) | (15.74) | (12.54) | (13.05) | |
Capital Expenditures |
(0.26) | (0.26) | (0.50) | (1.01) | |
| Other line items | |||||
Cash ROIC |
86.03% | 205.23% | 362.31% | 1,348.45% | |
Accounts Receivable Turnover |
3.53 | 1.40 | 1.09 | 0.05 | |
Accounts Payable Turnover |
0.20 | 0.27 | (0.19) | 0.30 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 38.44 | |
Average Days of Payables |
2,484.39 | 2,014.75 | (3,025.80) | 1,922.76 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 3.99 | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,432.08% | 1,437.82% | 1,738.22% | 5,229.11% | |
Share Based Compensation of Revenue |
308.60% | 292.66% | 164.35% | 116.45% | |
Interest Coverage |
(8.82) | (9.54) | (7.93) | (16.09) | |
Operating CF/Net income |
0.35 | 0.45 | 0.41 | 0.29 | |
Depreciation/Fixed assets |
3.61 | 0.12 | 0.09 | 0.08 | |
Capex/Depreciation |
(0.13) | (0.14) | (0.34) | (0.74) | |
Revenue per Share |
0.25 | 0.19 | 0.17 | 0.16 | |
Operating CF per Share |
(4.06) | (3.28) | (3.10) | (3.63) | |
Capex per Share |
(0.06) | (0.06) | (0.13) | (0.31) | |
Capex to Sales |
0.25 | 0.29 | 0.76 | 1.92 |
Columns are period end dates